Here's What's Behind Valeant Pharmaceuticals' 13% Drop
Shares of Valeant Pharmaceuticals (NYSE: VRX), the embattled drugmaker that's primarily grown through price hikes and acquisitions this decade, tumbled as much as 13% on Thursday after receiving a premarket rating downgrade from J.P. Morgan Securities.
The investment firm lowered its rating on Valeant Pharmaceuticals to "underweight," which is pretty much the equivalent of a "sell," from "neutral," which is where its opinion of Valeant had sat for more than a year. It there is a bright side here, J.P. Morgan did increase Valeant's price target by 20% to $12 from $10 (albeit the stock had climbed to north of $22 at yesterdays close).
Image source: Getty Images.
Source: Fool.com
Bausch Health Companies Inc. Aktie
5,18 €
-1,77 %
Deutliche Kaufsignale für Bausch Health Companies Inc. mit mehreren Buy- und keinen Sell-Einschätzungen.
Das Kursziel von 12 € für Bausch Health Companies Inc. impliziert eine potenzielle Verdopplung gegenüber dem aktuellen Kurs von 5.18 €.
